Conjunctiva reconstruction by induced differentiation of human amniotic epithelial cells

Yang, Song; Yang, Xueyi; Cao, Guoping

doi:10.4238/2015.october.29.2

Cited by 17 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These methods may be suitable for the reconstruction of the corneal epithelium. Additionally, hAECs were able to differentiate into conjunctival epithelium-like cells with partial physiological function upon culture with induced-denuded conjunctival matrix and conjunctival homogenate [ 49 ].…”

Section: Methodsmentioning

confidence: 99%

Application of human amniotic epithelial cells in regenerative medicine: a systematic review

Zhang

Lai

2020

Stem Cell Res Ther

View full text Add to dashboard Cite

Human amniotic epithelial cells (hAECs) derived from placental tissues have gained considerable attention in the field of regenerative medicine. hAECs possess embryonic stem cell-like proliferation and differentiation capabilities, and adult stem cell-like immunomodulatory properties. Compared with other types of stem cell, hAECs have special advantages, including easy isolation, plentiful numbers, the obviation of ethical debates, and non-immunogenic and non-tumorigenic properties. During the past two decades, the therapeutic potential of hAECs for treatment of various diseases has been extensively investigated. Accumulating evidence has demonstrated that hAEC transplantation helps to repair and rebuild the function of damaged tissues and organs by different molecular mechanisms. This systematic review focused on summarizing the biological characteristics of hAECs, therapeutic applications, and recent advances in treating various tissue injuries and disorders. Relevant studies published in English from 2000 to 2020 describing the role of hAECs in diseases and phenotypes were comprehensively sought out using PubMed, MEDLINE, and Google Scholar. According to the research content, we described the major hAEC characteristics, including induced differentiation plasticity, homing and differentiation, paracrine function, and immunomodulatory properties. We also summarized the current status of clinical research and discussed the prospects of hAEC-based transplantation therapies. In this review, we provide a comprehensive understanding of the therapeutic potential of hAECs, including their use for cell replacement therapy as well as secreted cytokine and exosome biotherapy. Moreover, we showed that the powerful immune-regulatory function of hAECs reveals even more possibilities for their application in the treatment of immune-related diseases. In the future, establishing the optimal culture procedure, achieving precise and accurate treatment, and enhancing the therapeutic potential by utilizing appropriate preconditioning and/or biomaterials would be new challenges for further investigation.

show abstract

Section: Methodsmentioning

confidence: 99%

Application of human amniotic epithelial cells in regenerative medicine: a systematic review

Zhang

Lai

2020

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…Conjunctival goblet cells secrete mucins that are glycoproteins that play an important role in the ocular surface barrier function [43]. Numerous studies have revealed that ECM from decellularized tissues may provide a vital and functional microenvironment to support the growth and differentiation of goblet cells [44]. Comparable goblet cells embedded in the epithelium were observed on top of DPP-Asp-hEGF, revealing no significant difference in the average count compared with NRC at day 28 (NRC: 6:80 ± 2:17, 9 Stem Cells International DPP-Asp-hEGF: 6:20 ± 1:92, counts/per vision, p > 0:05).…”

Section: Discussionmentioning

confidence: 99%

Crosslinked Decellularized Porcine Pericardium as a Substrate for Conjunctival Reconstruction

Chen

Deng

Luo

et al. 2022

Stem Cells International

View full text Add to dashboard Cite

Seeking for suitable conjunctival reconstruction substitutes to overcome the limitations of current substitutes, such as amniotic membrane, is urgent. Decellularized tissues have become a promising strategy for tissue engineering. In this study, we prepared decellularized porcine pericardium (DPP) scaffolds by the phospholipase A2 method and crosslinked them with aspartic acid (Asp) and human endothelial growth factor (hEGF) to enhance biological performance on the DPP, obtaining DPP-Asp-hEGF scaffolds. In vitro DPP showed lower apoptosis, highly desirable, well preservation of extracellular matrix components, and favorable macro-microstructure, which was confirmed by histology, immunofluorescence, electron microscopy, collagen and DNA quantification, and cytotoxicity assay, compared to the native porcine pericardium (NPP). The crosslinked efficacy of the DPP-Asp-hEGF was furtherer verified by in vitro experiments with Fourier transform infrared (FTIR) and X-ray diffraction (XRD). Through animal models of conjunctiva defect model, the DPP-Asp-hEGF revealed a closed, multilayer epithelium with an equal amount of goblet cells and no indication for conjunctival scarring after 28 days, compared to amniotic membrane (AM) groups and sham groups. These results suggested that DPP-Asp-hEGF can offer a good conjunctival reconstructive substitute both in structure and in function.

show abstract

“…An early attempt was published by Yang et al in 2015, in which the feasibility of the directed differentiation of human amniotic epithelial cells into the conjunctival epithelium was tested [ 80 ]. The transformation of conjunctival epithelial cells after AM transplantation to repair conjunctival damage due to burns had previously been reported [ 81 , 82 ].…”

Section: Potential Of Advanced Therapy Medicinal Products (Atmps) To Improve Conjunctival Treatmentmentioning

confidence: 99%

Is the Conjunctiva a Potential Target for Advanced Therapy Medicinal Products?

Diebold

García-Posadas

2021

Pharmaceutics

View full text Add to dashboard Cite

The conjunctiva is a complex ocular tissue that provides mechanical, sensory, and immune protection for the ocular surface. It is affected by many diseases through different pathological mechanisms. If a disease is not treated and conjunctival function is not fully restored, the whole ocular surface and, therefore, sight is at risk. Different therapeutic approaches have been proposed, but there are still unsolved conjunctival alterations that require more sophisticated therapeutic options. Advanced therapy medicinal products (ATMPs) comprise a wide range of products that includes cell therapy, tissue engineering, and gene therapy. To the best of our knowledge, there is no commercialized ATMP specifically for conjunctival treatment yet. However, the conjunctiva can be a potential target for ATMPs for different reasons. In this review, we provide an overview of the advances in experimental phases of potential ATMPs that primarily target the conjunctiva. Important advances have been achieved through the techniques of cell therapy and tissue engineering, whereas the use of gene therapy in the conjunctiva is still marginal. Undoubtedly, future research in this field will lead to achieving commercially available ATMPs for the conjunctiva, which may provide better treatments for patients.

show abstract

Conjunctiva reconstruction by induced differentiation of human amniotic epithelial cells

Cited by 17 publications

References 25 publications

Application of human amniotic epithelial cells in regenerative medicine: a systematic review

Application of human amniotic epithelial cells in regenerative medicine: a systematic review

Crosslinked Decellularized Porcine Pericardium as a Substrate for Conjunctival Reconstruction

Is the Conjunctiva a Potential Target for Advanced Therapy Medicinal Products?

Contact Info

Product

Resources

About